

de Recherche et d’Innovation
en Cybersécurité et Société
Aardema, F.; Bouchard, S.; Koszycki, D.; Lavoie, M. E.; Audet, J. -S.; O'Connor, K.
Evaluation of Inference-Based Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder: A Multicenter Randomized Controlled Trial with Three Treatment Modalities Article de journal
Dans: Psychotherapy and Psychosomatics, vol. 91, no 5, p. 348–359, 2022, ISSN: 00333190 (ISSN), (Publisher: S. Karger AG).
Résumé | Liens | BibTeX | Étiquettes: adult, aged, appraisal based cognitive behavioral therapy, article, clinical effectiveness, clinical evaluation, clinical outcome, clinical trial, cognitive behavioral therapy, Cognitive-behavioral therapy, controlled study, disease severity, female, human, Humans, inference based cognitive behavioral therapy, Inference-based approach, intermethod comparison, major clinical study, male, mindfulness, mindfulness-based stress reduction, multicenter study, obsessive compulsive disorder, Obsessive-Compulsive Disorder, patient dropout, procedures, randomized controlled trial, remission, treatment outcome, treatment refusal, Yale Brown Obsessive Compulsive Scale
@article{aardema_evaluation_2022,
title = {Evaluation of Inference-Based Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder: A Multicenter Randomized Controlled Trial with Three Treatment Modalities},
author = {F. Aardema and S. Bouchard and D. Koszycki and M. E. Lavoie and J. -S. Audet and K. O'Connor},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131012874&doi=10.1159%2f000524425&partnerID=40&md5=ff9a6095068e094c394e952eca4ca318},
doi = {10.1159/000524425},
issn = {00333190 (ISSN)},
year = {2022},
date = {2022-01-01},
journal = {Psychotherapy and Psychosomatics},
volume = {91},
number = {5},
pages = {348–359},
abstract = {Introduction: Inference-based cognitive-behavioral therapy (I-CBT) is a specialized psychological treatment for obsessive-compulsive disorder (OCD) without deliberate and prolonged exposure and response prevention (ERP) that focuses on strengthening reality-based reasoning and correcting the dysfunctional reasoning giving rise to erroneous obsessional doubts and ideas. Objective: The present study aimed to evaluate the effectiveness of I-CBT through a comparison with appraisal-based cognitive behavioral therapy (A-CBT) and an adapted mindfulness-based stress reduction (MBSR) intervention. Methods: This was a two-site, parallel-arm randomized controlled trial (RCT) comparing I-CBT with A-CBT. The MBSR intervention acted as a non-specific active control condition. Following formal evaluation, 111 participants diagnosed with OCD were randomly assigned. The principal outcome measure was the Yale-Brown Obsessive-Compulsive Scale. Results: All treatments significantly reduced general OCD severity and specific symptom dimensions without a significant difference between treatments. I-CBT was associated with significant reductions in all symptom dimensions at post-test. Also, I-CBT led to significantly greater improvement in overvalued ideation, as well as significantly higher rates of remission as compared to MBSR at mid-test. Conclusions: I-CBT and MBSR appear to be effective, alternative treatment options for those with OCD that yield similar outcomes as A-CBT. I-CBT may have an edge in terms of the rapidity by which patients reach remission, its generalizability across symptom dimension, its potentially higher level of acceptability, and effectiveness for overvalued ideation. Future research is needed to assess whether additional alternative treatments options can help to increase the number of people successfully treated. © 2022 The Author(s). Published by S. Karger AG, Basel.},
note = {Publisher: S. Karger AG},
keywords = {adult, aged, appraisal based cognitive behavioral therapy, article, clinical effectiveness, clinical evaluation, clinical outcome, clinical trial, cognitive behavioral therapy, Cognitive-behavioral therapy, controlled study, disease severity, female, human, Humans, inference based cognitive behavioral therapy, Inference-based approach, intermethod comparison, major clinical study, male, mindfulness, mindfulness-based stress reduction, multicenter study, obsessive compulsive disorder, Obsessive-Compulsive Disorder, patient dropout, procedures, randomized controlled trial, remission, treatment outcome, treatment refusal, Yale Brown Obsessive Compulsive Scale},
pubstate = {published},
tppubtype = {article}
}
Maïano, C.; Coutu, S.; Tracey, D.; Bouchard, S.; Lepage, G.; Morin, A. J. S.; Moullec, G.
Prevalence of anxiety and depressive disorders among youth with intellectual disabilities: A systematic review and meta-analysis Article de journal
Dans: Journal of Affective Disorders, vol. 236, p. 230–242, 2018, ISSN: 01650327, (Publisher: Elsevier B.V.).
Résumé | Liens | BibTeX | Étiquettes: Adolescent, adolescent disease, Anxiety disorder, Anxiety Disorders, Child, childhood disease, Depression, Depressive Disorder, dysthymia, Dysthymic Disorder, female, generalized anxiety disorder, human, Humans, infant, Intellectual Disability, intellectual impairment, Major, major depression, male, meta analysis, Newborn, obsessive compulsive disorder, Obsessive-Compulsive Disorder, Preschool, preschool child, Prevalence, priority journal, psychology, review, systematic review, Young Adult
@article{maiano_prevalence_2018,
title = {Prevalence of anxiety and depressive disorders among youth with intellectual disabilities: A systematic review and meta-analysis},
author = {C. Maïano and S. Coutu and D. Tracey and S. Bouchard and G. Lepage and A. J. S. Morin and G. Moullec},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046664327&doi=10.1016%2fj.jad.2018.04.029&partnerID=40&md5=504c552402432a5b6443d07f63170403},
doi = {10.1016/j.jad.2018.04.029},
issn = {01650327},
year = {2018},
date = {2018-01-01},
journal = {Journal of Affective Disorders},
volume = {236},
pages = {230–242},
abstract = {Background: The purpose of this meta-analytic study was to determine the pooled prevalence estimates of anxiety and depressive disorders among children and adolescents with intellectual disabilities (ID) and to assess the extent to which these pooled prevalence rates differed according to studies’ characteristics. Method: A systematic literature search was performed in nine databases and 21 studies, published between 1975 and 2015, met the inclusion criteria. Results: The resulting pooled prevalence estimates of combined subtypes of anxiety and depressive disorders were respectively (a) 5.4% and 2.8% across samples; (b) 1.2% and 0.03% among children; and (c) 7.9% and 1.4% among adolescents. Pooled prevalence estimates for specific subtypes of anxiety disorders ranged from (a) 0.2% to 11.5% across samples; (b) 0.7% to 17.6% among children; and (c) 0.6% to 19.8% among adolescents. Pooled prevalence estimates of dysthymic disorder and major depressive disorder were respectively (a) 3.4% and 2.5% across samples; (b) 2.1% and 3.2% among children; and (c) 6.9% and 5.7% among adolescents. Finally, subgroup analyses showed significant variations in the pooled prevalence estimates of combined subtypes of anxiety disorders, obsessive-compulsive disorder, and generalized anxiety disorder; and combined subtypes of depressive disorders. Limitations: The present findings of this meta-analysis should be interpreted with caution given several limitations related to the characteristics of the populations, diagnostic method and sampling method. Conclusion: Findings provide recommendations for future studies investigating psychological disorders among youth with ID, as well as how clinicians and policy makers can improve diagnostic practices and support for youth with ID. © 2018 Elsevier B.V.},
note = {Publisher: Elsevier B.V.},
keywords = {Adolescent, adolescent disease, Anxiety disorder, Anxiety Disorders, Child, childhood disease, Depression, Depressive Disorder, dysthymia, Dysthymic Disorder, female, generalized anxiety disorder, human, Humans, infant, Intellectual Disability, intellectual impairment, Major, major depression, male, meta analysis, Newborn, obsessive compulsive disorder, Obsessive-Compulsive Disorder, Preschool, preschool child, Prevalence, priority journal, psychology, review, systematic review, Young Adult},
pubstate = {published},
tppubtype = {article}
}
Ikic, V.; Bélanger, C.; Bouchard, S.; Gosselin, P.; Langlois, F.; Labrecque, J.; Dugas, M. J.; Marchand, A.
Reduction in costs after treating comorbid panic disorder with agoraphobia and generalized anxiety disorder Article de journal
Dans: Journal of Mental Health Policy and Economics, vol. 20, no 1, p. 11–20, 2017, ISSN: 10914358, (Publisher: ICMPE).
Résumé | Liens | BibTeX | Étiquettes: adult, agoraphobia, Anxiety disorder, Anxiety Disorders, article, cognitive behavioral therapy, cognitive therapy, comorbidity, controlled study, dysthymia, economics, female, follow up, generalized anxiety disorder, health care cost, Health Care Costs, human, Humans, major clinical study, major depression, male, Mental health, obsessive compulsive disorder, panic, Panic Disorder, phobia, posttraumatic stress disorder, procedures, Quebec, social phobia, statistics and numerical data
@article{ikic_reduction_2017,
title = {Reduction in costs after treating comorbid panic disorder with agoraphobia and generalized anxiety disorder},
author = {V. Ikic and C. Bélanger and S. Bouchard and P. Gosselin and F. Langlois and J. Labrecque and M. J. Dugas and A. Marchand},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018690998&partnerID=40&md5=0d0600e6dd4e2a381f733ac063d639dc},
issn = {10914358},
year = {2017},
date = {2017-01-01},
journal = {Journal of Mental Health Policy and Economics},
volume = {20},
number = {1},
pages = {11–20},
abstract = {Background: Panic disorder with agoraphobia (PDA) and generalized anxiety disorder (GAD) are impairing and costly disorders that are often misdiagnosed and left untreated despite multiple consultations. These disorders frequently co-occur, but little is known about the costs associated with their comorbidity and the impact of cognitive-behavioral therapy (CBT) on cost reduction. Aims of the Study: The first objective of this study was to assess the mental health-related costs associated with the specific concomitance of PDA and GAD. The second aim was to determine whether there is a reduction in direct and indirect mental healthrelated costs following conventional CBT for the primary disorder only (PDA or GAD) or combined CBT adapted to the comorbidity (PDA and GAD). Methods: A total of 123 participants with a double diagnosis of PDA and GAD participated in this study. Direct and indirect mental health-related costs were assessed and calculated from a societal perspective at the pre-Test, the post-Test, and the three-month, sixmonth and one-year follow-ups. Results: At the pre-Test, PDA-GAD comorbidity was found to generate a mean total cost of CAD2,000.48 (SD = 2,069.62) per participant over a three-month period. The indirect costs were much higher than the direct costs. Both treatment modalities led to significant and similar decreases in all cost categories from the pretest to the post-Test. This reduction was maintained until the oneyear follow-up. Discussion: Methodological choices may have underestimated cost evaluations. Nonetheless, this study supports the cost offset effects of both conventional CBT for primary PDA or GAD and combined CBT for PDA-GAD comorbidity. Implications for Healthcare Provision and Use: Treatment of comorbid and costly disorders with evidence-based treatments such as CBT may lead to considerable economic benefits for society. Implications for Health Policies: Considering the limited resources of healthcare systems, it is important to make choices that will lead to better accessibility of quality services. The application of CBT for PDA, GAD or both disorders and training mental health professionals in this therapeutic approach should be encouraged. Additionally, it would be favorable for insurance plans to reimburse employees for expenses associated with psychological treatment for anxiety disorders. Implications for Further Research: In addition to symptom reduction, it would be of great pertinence to explore which factors can contribute to reducing direct and indirect mental health-related costs. © 2017 ICMPE.},
note = {Publisher: ICMPE},
keywords = {adult, agoraphobia, Anxiety disorder, Anxiety Disorders, article, cognitive behavioral therapy, cognitive therapy, comorbidity, controlled study, dysthymia, economics, female, follow up, generalized anxiety disorder, health care cost, Health Care Costs, human, Humans, major clinical study, major depression, male, Mental health, obsessive compulsive disorder, panic, Panic Disorder, phobia, posttraumatic stress disorder, procedures, Quebec, social phobia, statistics and numerical data},
pubstate = {published},
tppubtype = {article}
}
Laforest, M.; Bouchard, S.; Bossé, J.; Mesly, O.
Dans: Frontiers in Psychiatry, vol. 7, no JUN, 2016, ISSN: 16640640 (ISSN), (Publisher: Frontiers Research Foundation).
Résumé | Liens | BibTeX | Étiquettes: adult, aged, article, CBT, clinical effectiveness, cognitive behavioral therapy, disease severity, exposure, female, generalized anxiety disorder, human, hypnosis, male, obsessive compulsive disorder, Obsessive-Compulsive Disorder, pilot study, psychologic assessment, Response prevention, self report, treatment duration, treatment outcome, treatment response, virtual reality, Yale Brown Obsessive Compulsive Scale
@article{laforest_effectiveness_2016,
title = {Effectiveness of in virtuo exposure and response prevention treatment using cognitive-behavioral therapy for obsessive-compulsive disorder: A study based on a single-case study protocol},
author = {M. Laforest and S. Bouchard and J. Bossé and O. Mesly},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84977551825&doi=10.3389%2ffpsyt.2016.00099&partnerID=40&md5=8aaf926230112d06a0c1e629e49b51c6},
doi = {10.3389/fpsyt.2016.00099},
issn = {16640640 (ISSN)},
year = {2016},
date = {2016-01-01},
journal = {Frontiers in Psychiatry},
volume = {7},
number = {JUN},
abstract = {Obsessive-compulsive disorder (OCD) is characterized by the presence of distressing, recurrent and intrusive thoughts, impulses, or doubts as well as behavioral or mental rituals. OCD has various subtypes, including the fear of contamination in which individuals fear bacteria, germs, disease, or bodily secretions, and engage in clinically significant cleaning and avoidance rituals. Cognitive-behavioral therapy (CBT) is an effective treatment for OCD and involves, among other therapeutic strategies, exposing patients to feared stimuli while preventing them to engage in compulsive behaviors. In recent years, virtual reality (VR) has shown the potential of in virtuo exposure with people suffering from anxiety disorders and OCD. The objective of this pilotstudy is to examine the effectiveness of a CBT program where exposure in conducted in virtuo. Three adults suffering from OCD with a dominant subtype of contamination were enrolled in a single-case design with multiple baselines across participants. The presence and intensity of obsessions and compulsions were assessed daily during baselines of 3-, 4-, or 5-week, and a 12-session treatment. Follow-up information was gathered after 4 and 8 months. Treatment outcome is assessed with visual inspection of the graphs and ARMA time-series analyses. Clinical information, self-reports, and details of the treatment are provided for each patient. Statistical analyses for the time-series data revealed a statistically significant improvement in all three participants, but global improvement is considered positive for only two. This study innovates in proving preliminary support for the usefulness of VR in the CBT of OCD with contamination features. © 2016 Laforest, Bouchard, Bossé and Mesly.},
note = {Publisher: Frontiers Research Foundation},
keywords = {adult, aged, article, CBT, clinical effectiveness, cognitive behavioral therapy, disease severity, exposure, female, generalized anxiety disorder, human, hypnosis, male, obsessive compulsive disorder, Obsessive-Compulsive Disorder, pilot study, psychologic assessment, Response prevention, self report, treatment duration, treatment outcome, treatment response, virtual reality, Yale Brown Obsessive Compulsive Scale},
pubstate = {published},
tppubtype = {article}
}
Katzman, M. A.; Bleau, P.; Blier, P.; Chokka, P.; Kjernisted, K.; Ameringen, M. Van; Antony, M. M.; Bouchard, S.; Brunet, A.; Flament, M.; Rabheru, K.; Grigoriadis, S.; Richter, P. M. A.; Mendlowitz, S.; O'Connor, K.; Robichaud, M.; Walker, J. R.; Asmundson, G.; Klassen, L. R.; Lam, R. W.; McIntyre, R. S.; Szpindel, I.
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders Article de journal
Dans: BMC Psychiatry, vol. 14, no SUPPL.1, 2014, ISSN: 1471244X (ISSN), (Publisher: BioMed Central Ltd.).
Résumé | Liens | BibTeX | Étiquettes: agoraphobia, Anxiety disorder, Anxiety Disorders, benzodiazepine derivative, buspirone, Canada, clinical trial, clomipramine, comorbidity, duloxetine, escitalopram, fluoxetine, fluvoxamine, fluvoxamine maleate, GAD, generalized anxiety disorder, guidelines, human, Humans, obsessive compulsive disorder, Obsessive-Compulsive Disorder, OCD, panic, Panic Disorder, paroxetine, periodic medical examination, pharmacotherapy, Post-Traumatic, posttraumatic stress disorder, practice guideline, Practice Guidelines as Topic, psychotherapy, PTSD, recommendations, review, sertraline, social anxiety disorder, social phobia, special populations, Specific phobia, Stress Disorders, venlafaxine
@article{katzman_canadian_2014,
title = {Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders},
author = {M. A. Katzman and P. Bleau and P. Blier and P. Chokka and K. Kjernisted and M. Van Ameringen and M. M. Antony and S. Bouchard and A. Brunet and M. Flament and K. Rabheru and S. Grigoriadis and P. M. A. Richter and S. Mendlowitz and K. O'Connor and M. Robichaud and J. R. Walker and G. Asmundson and L. R. Klassen and R. W. Lam and R. S. McIntyre and I. Szpindel},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903778611&doi=10.1186%2f1471-244X-14-S1-S1&partnerID=40&md5=4787fc6f97c204c1428770a5e4a57a00},
doi = {10.1186/1471-244X-14-S1-S1},
issn = {1471244X (ISSN)},
year = {2014},
date = {2014-01-01},
journal = {BMC Psychiatry},
volume = {14},
number = {SUPPL.1},
abstract = {Background: Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.Methods: These guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980-2012). Treatment strategies were rated on strength of evidence, and a clinical recommendation for each intervention was made, based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.Results: These guidelines are presented in 10 sections, including an introduction, principles of diagnosis and management, six sections (Sections 3 through 8) on the specific anxiety-related disorders (panic disorder, agoraphobia, specific phobia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), and two additional sections on special populations (children/adolescents, pregnant/lactating women, and the elderly) and clinical issues in patients with comorbid conditions.Conclusions: Anxiety and related disorders are very common in clinical practice, and frequently comorbid with other psychiatric and medical conditions. Optimal management requires a good understanding of the efficacy and side effect profiles of pharmacological and psychological treatments. © 2014 Katzman et al.},
note = {Publisher: BioMed Central Ltd.},
keywords = {agoraphobia, Anxiety disorder, Anxiety Disorders, benzodiazepine derivative, buspirone, Canada, clinical trial, clomipramine, comorbidity, duloxetine, escitalopram, fluoxetine, fluvoxamine, fluvoxamine maleate, GAD, generalized anxiety disorder, guidelines, human, Humans, obsessive compulsive disorder, Obsessive-Compulsive Disorder, OCD, panic, Panic Disorder, paroxetine, periodic medical examination, pharmacotherapy, Post-Traumatic, posttraumatic stress disorder, practice guideline, Practice Guidelines as Topic, psychotherapy, PTSD, recommendations, review, sertraline, social anxiety disorder, social phobia, special populations, Specific phobia, Stress Disorders, venlafaxine},
pubstate = {published},
tppubtype = {article}
}